anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a phase II multicenter study designed in two phases. A total of 32 patients will be included in 10 hospitals belonging to the Spanish Group for Research in Sarcomas (GEIS). Selection criteria are: patients with localized soft tissue sarcoma from the extremities or trunk with high-risk features (\>5 cm and grade 2-3), or recurrences after prior inadequate surgery. The treatment schedule will be: initial biopsy, 3 cycles of high-dose Ifosfamide, 12 gr/m2 in 5 days, concurrent with Radiotherapy 50 Gy, and subsequent wide surgery. To assess the predictive factors of response to the combination therapy, DNA and RNA extraction will be performed on the pretreatment biopsies. DNA will be used to hybridize Affymetrix GeneChip® Human Mapping 500K Array, which allows for the study of 500000 SNPs throughout the genome. The expression of 39000 RNA transcripts will be evaluated employing the Affymetrix Genechip Human Genome HG-U133 Plus 2.0, and validated by real-time RT-PCR.
An example medical device includes a physiological measurement device and a computing device. The computing device includes a device management engine and a data connectivity engine. The device management engine is configured to receive data captured by the physiological measurement device. The data captured by the physiological measurement device is formatted in a first data format. The device connectivity engine is further configured to transform the data captured by the physiological measurement device into an array of key-value pairs. The device connectivity engine is further configured to populate a template with at least some of the values from the key-value pairs to generate a populated template. The populated template includes at least a portion of the data captured by the physiological measurement device in a second data format. The device connectivity engine is further configured to transmit the populated template.
Our laboratory at Meir Medical Center, Kfar Saba, is the country's main center for neutrophil function, and serves about 80% of Israel's population. Patients are referred subsequent to recurrent, persistent, or unusual infections and after completing preliminary screening of the immune system and ruling out a humoral, cellular or complement immune deficiency. Initial workup includes chemotaxis, superoxide production (SOP), and bactericidal activity (BA). Based on test findings, further evaluation for a qualitative phagocytic disorder is conducted. Overall, impairment of phagocytic activity is found in about 33% (impaired chemotaxis in 16%, SOP in 6%, and BA in 24%). In the other 67%, no impairment of the immune function is found that can explain their tendency for recurrent pyogenic infections.

In 2004 a novel function of the neutrophil was identified: formation of neutrophil extracellular traps (NETs). Apparently, neutrophils are able to extrude part of their cellular contents in the form of DNA, histones and proteases, to form extra cellular NETS that trap and kill bacterial pathogens without the need for phagocytosis. We aim to study if pathological NETs formation could be the underlying pathology among these patients with recurrent infections and a normal screening of the immune system.
Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative \& Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
Participants enrolled in this cohort will receive the RP2D based on the safety and efficacy profile determined in the Phase 1 cohorts. Participants will receive the RP2D dose of olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 at the RP2D for the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first.
BACKGROUND: Lysyl oxidase enzymes (LOXs), as extracellular matrix (ECM) protein regulators, play vital roles in tumor progression by remodeling the tumor microenvironment. However, their roles in glioblastoma (GBM) have not been fully elucidated.
METHODS: The genetic alterations and prognostic value of LOXs were investigated via cBioPortal. The correlations between LOXs and biological functions/molecular tumor subtypes were explored in The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA). After Kaplan‒Meier and Cox survival analyses, a Loxl1-based nomogram and prognostic risk score model (PRSM) were constructed and evaluated by time-dependent receiver operating characteristic curves, calibration curves, and decision curve analyses. Tumor enrichment pathways and immune infiltrates were explored by single-cell RNA sequencing and TIMER. Loxl1-related changes in tumor viability/proliferation and invasion were further validated by CCK-8, western blot, wound healing, and Transwell invasion assays.
RESULTS: GBM patients with altered LOXs had poor survival. Upregulated LOXs were found in IDH1-wildtype and mesenchymal (not Loxl1) GBM subtypes, promoting ECM receptor interactions in GBM. The Loxl1-based nomogram and the PRSM showed high accuracy, reliability, and net clinical benefits. Loxl1 expression was related to tumor invasion and immune infiltration (B cells, neutrophils, and dendritic cells). Loxl1 knockdown suppressed GBM cell proliferation and invasion by inhibiting the EMT pathway (through the downregulation of N-cadherin/Vimentin/Snai1 and the upregulation of E-cadherin).
CONCLUSION: The Loxl1-based nomogram and PRSM were stable and individualized for assessing GBM patient prognosis, and the invasive role of Loxl1 could provide a promising therapeutic strategy.
The use of benzodiazepines, including chlordiazepoxide hydrochloride, a component of chlordiazepoxide hydrochloride and clidinium bromide capsules, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE). 

Before prescribing chlordiazepoxide hydrochloride and clidinium bromide capsules and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of chlordiazepoxide hydrochloride and clidinium bromide capsules, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of chlordiazepoxide hydrochloride and clidinium bromide capsules along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
When a novel stimulus (oddball) appears after repeated presentation of an identical stimulus, the oddball is perceived to last longer than the repeated stimuli, a phenomenon known as the oddball effect. We investigated whether the perceptual or physical differences between the repeated and oddball stimuli are more important for the oddball effect. To manipulate the perceptual difference while keeping their physical visual features constant, we used the Thatcher illusion, in which an inversion of a face hinders recognition of distortion in its facial features. We found that the Thatcherized face presented after repeated presentation of an intact face induced a stronger oddball effect when the faces were upright than when they were inverted (Experiment 1). However, the difference in the oddball effect between face orientations was not observed when the intact face was presented as the oddball after repeated presentation of a Thatcherized face (Experiment 2). These results were replicated when participants performed both the intact-repeated and Thatcherized-repeated conditions in a single experiment (Experiment 3). Two control experiments confirmed that the repeated presentation of the preceding stimuli is necessary for the difference in duration distortion to occur (Experiments 4 and 5). The results suggest the considerable role of perceptual processing in the oddball effect. We discuss the discrepancy in the results between the intact-repeated and Thatcherized-repeated conditions in terms of predictive coding.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to children's anesthesiology and resuscitation science, and can be used as prevention of bronchopulmonary dysplasia in newborn babies with very low and extremely low body weight. For this purpose, to newborn babies, who have been for not less than 7 days of life on non-invasive ALV in mode Biphasic/DuoPAP through nasal cannulas or in mode CPAP through nasal cannulas and on invasive ALV, introduced is "Surfactant BL" in single dose 53-75 mg/kg. Introduction is performed from 8 to 27 days of life inclusive, in sessions 10-15 minutes long depending on volume of Surfactant BL suspension by nebuliser with aerosol generator OnQ Aeroneb« Pro. At most 5 sessions are carried out. ^ EFFECT: method makes it possible to prevent development of bronchopulmonary dysplasia in said category of patients due to introduction of surfactant BL, which contains surfactant-associated proteins by means of nebuliser, making it possible to introduce medication at rate, optimal for alveolar deposition, preserving its molecular integrity. ^ 4 tbl, 4 ex
A method and composition for a film forming antimicrobial material for animal skin wherein said film is resistant to body fluids and provides long term protection against microorganisms. The composition comprises an alcohol soluble carboxylated polycrylate wherein is added an antimicrobial agent, a topical adhesion promoter, and a difunctional amide which crosslinks said polymer as said solvent evaporates. The topical film so formed does not interfere with respiratory processes and is inert to blood, urine, gastric acids, perspiration, saline solutions and the like. Once formed, said film will not resolubilize in alcohol or other common sterilants. Said topical film adheres to tissue and is resistant to physical removal and to abrasion. Film longevity is in excess of 2 days. Substantial protection is provided against pathogenic bacteria and fungi often implicated in hospital infections and thus can serve as a presurgical dressing, preparation agent, as well as in post-surgical prophylaxis.
The worldwide HIV epidemic highlights the importance of developing an affordable, globally successful vaccine for HIV prevention. The VRC-HIVDNA009-00-VP vaccine used in this study was developed to incorporate HIV genes from multiple virus clades, representing the viral subtypes responsible for about 90% of new HIV infections in the world. The purpose of this study is to determine the safety and immunogenicity of VRC-HIVDNA009-00-VP in healthy, HIV uninfected individuals.

Participants will be randomly assigned to one of three groups and will be followed for one year. Study injections will be given by needle-free intramuscular injection at the start of study and at Months 1 and 2. Group 1 will receive 3 injections of the study vaccine; Group 2 will receive 2 injections of the study vaccine (at start and Month 2) and injection of placebo (at Month 1); Group 3 will receive 3 injections of placebo. After a screening visit, study visits will occur at enrollment (initial injection) followed by 5 visits every 14 days for the first 2.5 months, with three additional visits at Months 6, 9, and 12. All participants will undergo physical exams, blood and urine tests to assess measures of health, and blood tests to assess HIV infection and immune response to the injections.
Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m\^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
The Primary Objective of this study is to develop and validate the algorithm needed to detect upright posture with a waist 3-axis accelerometer. A Secondary Objective is to determine the performance reliability of posture detection of the thigh and waist accelerometers when exposed to activities of daily living (standing, walking, climbing stairs). We will test the primary and secondary objectives in normal subjects using a single study design. Studies for both objectives will be conducted simultaneously on each subject on a single study day. Normal subjects will wear a device with the waist accelerometer incorporated within the controller box.

Subjects will be instrumented with the abdominal belt and controller box containing the waist accelerometer sensor. The external accelerometer sensor will be fixed with a Velcro around the thigh. In addition, subjects will wear two commercially available accelerometer sensors: 1) the ActivPal on the thigh of the other leg, and 2) an external accelerometer attached to the back of the belt at the level of the waist. The ActivPal can detect the upright posture but cannot distinguish between supine and sitting. The sensor placed on the back will be less affected by belly size in case of obese subjects. Both sensors will be used as a reference and for comparison. We will record all accelerometer signals during different body positions and activities. The activities will include lying down, sitting, getting up and standing still, walking, and climbing up and down steps for about one minute each for a total of 15-20 minutes per group of activities. Participants will perform 3 groups of activities. The order of activities within each group will be randomized. We might also ask you to perform \~3 small jumps to synchronize the sensors at the beginning, middle and the end of each set of activities.
BACKGROUND: Cardiopulmonary bypass (CPB) is associated with intravascular hemolysis which depletes endogenous nitric oxide (NO). The impact of hemolysis on pulmonary arterial compliance (PAC) and right ventricular systolic function has not been explored yet. We hypothesized that decreased NO availability is associated with worse PAC and right ventricular systolic function after CPB.
METHODS: This is a secondary analysis of an observational cohort study in patients undergoing cardiac surgery with CPB at Massachusetts General Hospital, USA (2014-2015). We assessed PAC (stroke volume/pulmonary artery pulse pressure ratio), and right ventricular function index (RVFI) (systolic pulmonary arterial pressure/cardiac output), as well as NO consumption at 15 min, 4 h and 12 h after CPB. Patients were stratified by CPB duration. Further, we assessed the association between changes in NO consumption with PAC and RVFI between 15min and 4 h after CPB.
RESULTS: PAC was lowest at 15min after CPB and improved over time (n = 50). RVFI was highest -worse right ventricular function- at CPB end and gradually decreased. Changes in hemolysis, PAC and RVFI differed over time by CPB duration. PAC inversely correlated with total pulmonary resistance (TPR). TPR and PAC positively and negatively correlated with RVFI, respectively. NO consumption between 15min and 4 h after CPB correlated with changes in PAC (-0.28 ml/mmHg, 95%CI -0.49 to -0.01, p = 0.012) and RVFI (0.14 mmHg*L-1*min, 95%CI 0.10 to 0.18, p < 0.001) after multivariable adjustments.
CONCLUSION: PAC and RVFI are worse at CPB end and improve over time. Depletion of endogenous NO may contribute to explain changes in PAC and RVFI after CPB.
The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
BACKGROUND: Chronic diseases remain a significant contributor to both mortality and disability in our modern world. Physical inactivity and an unhealthy diet are recognized as significant behavioral risk factors for chronic diseases, which can be influenced by the built environment and socio-economic status (SES). This study aims to investigate the relationship between the built environment, SES, and lifestyle factors with chronic diseases.
METHODS: The current study was conducted in Mashhad's Persian cohort, which included employees from Mashhad University of Medical Sciences (MUMS). In the study, 5,357 participants from the cohort were included. To assess the state of the built environment in Mashhad, a Geographic Information System (GIS) map was created for the city and participants in the Persian Mashhad study. Food intake and physical exercise were used to assess lifestyle. A food frequency questionnaire (FFQ) was used to assess food intake. To assess food intake, the diet quality index was computed. To assess the link between variables, the structural model was created in accordance with the study's objectives, and partial least square structural equation modeling (PLS-SEM) was utilized.
RESULTS: The chronic diseases were positively associated with male sex (p < 0.001), married (p < 0.001), and higher age (p < 0.001). The chronic diseases were negatively associated with larger family size (p < 0.05), higher SES (p < 0.001), and higher diet quality index (DQI) (p < 0.001). No significant relationship was found between chronic disease and physical activity.
CONCLUSION: Food intake and socioeconomic status have a direct impact on the prevalence of chronic diseases. It seems that in order to reduce the prevalence of chronic diseases, increasing economic access, reducing the class gap and increasing literacy and awareness should be emphasized, and in the next step, emphasis should be placed on the built environment.
FIELD: medicine. SUBSTANCE: method involves perforating injured sinus in the position of typical puncture, its washing, filling with medication solution, exposing to ultrasonic low frequency radiation and removing the used up solution. After perforating with puncture needle and washing the sinus, the puncture opening is widened. After removing the used up solution, antiseptic jet and aerosol spray coating and laser irradiation are additionally applied at the granulation stage and pathological focus epithelialization stage. The device has power supply source, acoustic unit and emitter for carrying out intranasal action upon the pathological focus. The device is additionally provided with stopping needle having rest flange. The emitter is axially movably enclosed into the stopping needle through guiding bushing so that coaxial clearance is formed between the external diameter of the emitter and internal diameter of the needle. The clearance enables communication with hydraulic system for delivering and discharging drug solution through cavity in guiding bushing and coaxial openings in the guiding bushing and the flange. Fixing screw is made in the guiding bushing. Groove coupled with the screw is made in the cylindrical part of the emitter. EFFECT: accelerated treatment course. 7 cl, 6 dwg tbl
BACKGROUND: Yangyinghuoxue decoction (YYHXD) is a Traditional Chinese medicine (TCM) compound with satisfactory clinical efficacy in the treatment of hepatic fibrosis (HF). However, the pharmacological molecular mechanisms of YYHXD in the treatment of hepatic fibrosis have not yet been clarified.
OBJECTIVE: To determine the pharmacological mechanisms of YYHXD for the treatment of hepatic fibrosis via network pharmacology analysis combined with experimental verification.
METHODS: First, the bioactive ingredients and potential targets of YYHXD and HF-related targets were retrieved from the online databases and literatures. Next, the "herb-ingredient-target-disease" network and PPI network were constructed for topological analyses and key active compounds and targets screening. Enrichment analyses were performed to identify the critical biological processes and signaling pathways. Then, the molecular docking experiment was performed to initially validate the network pharmacology prediction results. Finally, the antifibrotic effect and pharmacological mechanisms of YYHXD were investigated in CCl4 induced liver fibrosis in rats.
RESULTS: In total, 141 active compounds in YYHXD, 637 YYHXD-related targets and 1598 liver fibrosis-related targets were identified. Among them, 69 overlapped targets were finally obtained. Network analysis screened 5 critical bioactive components and 34 key targets. Functional enrichment analysis indicated that YYHXD obviously influenced biological processes such as oxidative stress, cellular inflammation and hepatocyte apoptosis and signaling pathways such as PI3K-Akt, Apoptosis, and JAK-STAT in the treatment of HF. The molecular docking results suggested that the YYHXD may have a direct impact on the PI3K-Akt signaling pathway. Further, in vivo experiment indicated that YYHXD treatment not only reduced liver injury and protected liver function, but also decrease the apoptosis of hepatic parenchyma cells, reducing inflammatory and attenuating oxidative stress. Moreover, YYHXD significantly attenuated the upregulation of target proteins enriched in PI3K signaling pathway, including P-PI3K, P-Akt1, HSP90, MYC, p53.
CONCLUSIONS: The mechanisms of YYHXD against liver fibrosis were involved in multiple ingredients, multiple targets and multiple signaling pathways. The PI3K/Akt pathway could be the most important pharmacological mechanism of YYHXD therapy for liver fibrosis.